Premier Alternatives

Cambrian Bio

Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)

Developer of a portfolio of medicines designed to target the causes of age-related diseases. Cambrian Bio is based in New York, NY and was founded in 2019. Its last reported valuation was $180 million in Aug 2023. It has raised $204 million across 1 recorded round; the latest was a $23.8 million later-stage round in Dec 2025.

Last reported valuation
$180.0M
Oct 2026
Priced at
—
Total raised
$204.1M
Last round
Later Stage VC
Dec 2025

Cambrian Bio key facts

as of Oct 2026
  • Developer of a portfolio of medicines designed to target the causes of age-related diseases.
  • Cambrian Bio is valued at approximately $180.0M as of Oct 2026 (last reported valuation).
  • It has raised $204.1M across 1 recorded rounds; the latest was Later Stage VC ($23.8M) in Dec 2025.
  • Notable investors include Alumni Ventures, FJ Labs, Gaingels, RA Capital Management, Capital Factory — 41 tracked in total.
  • 1 investment vehicle was formed to buy Cambrian Bio shares in the last 12 months, reporting $820K sold to 43 investors, per SEC Form D filings.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$180.0M

Cambrian Bio's last reported valuation, Aug 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Cambrian Bio with a free account
  • ·The complete investor list: 41 names
  • ·Watch Cambrian Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Cambrian Bio funding rounds

1 rounds
Dec 2025Later Stage VC$23.8M▮
Full funding history →

Vehicles formed to buy Cambrian Bio shares

secondary demand · SEC Form D filings

In the last 12 months, 1 investment vehicle were formed to buy Cambrian Bio shares, reporting $820K sold to 43 investors. Most recent filing Jun 2026.

The vehicle list — each sponsor, filing date, amount sold and investor count — is a Pro table. Unlock the 1 vehicle →

Membership and data by Private Market View

Companies with the most vehicle activity →

Cambrian Bio valuation

Cambrian Bio's last reported valuation was $180 million in Aug 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Cambrian Bio raised?

Cambrian Bio has raised $204 million in total; 1 of its rounds is on record. The largest on record was a $23.8 million later-stage round in Dec 2025.

Institutional holders and vehicles

In the last 12 months, 1 investment vehicle was formed to buy Cambrian Bio shares, reporting $819,890 sold to 43 investors, per SEC Form D filings (most recent Jun 2026).

Cambrian Bio investors

41 investors are on record for Cambrian Bio, including Alumni Ventures, FJ Labs, Gaingels and RA Capital Management. By type, the record holds 15 venture capital firms, 3 family offices and 2 hedge funds. The later-stage round in Dec 2025 drew 11 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Ajax Therapeutics ($193 million), Kinaset Therapeutics ($186 million) and Gordian Biotechnology ($170 million).

About Cambrian Bio

Developer of a portfolio of medicines designed to target the causes of age-related diseases. The company develops therapies and medicines to create interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life, enabling scientists to transmit their discoveries from the lab into the clinic and bring medicines to patients in need.

Industry
Drug Discovery
Sector
Healthcare
HQ
New York, NY, United States
Founded
2019
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.